Body Pharm BPC-157 10mg is a lyophilised research-grade pentadecapeptide vial sold in South Africa for in vitro and preclinical tissue-repair studies, not for human or veterinary use under SAHPRA's unregistered-medicines framework.
South African researchers should check three things before ordering: batch-specific HPLC documentation (typically ≥98% for research-grade material, with Certificate of Analysis provided on request); salt form (acetate, arginine salt, or free acid, confirm with the supplier); and ZAR pricing. The 5mg Body Pharm vial was listed at R391 in 2024, so the 10mg vial typically costs roughly double.
As of May 2026, no completed human clinical trial of BPC-157 is registered on ClinicalTrials.gov or SANCTR (South African National Clinical Trials Register). All efficacy claims below apply strictly to preclinical models.
Key Takeaways
- BPC-157 is a 15-amino-acid research peptide (CAS 137525-51-0) with no registered human clinical trials in South Africa or globally as of May 2026
- Preclinical rodent studies report tissue-repair benefits in tendon, ligament and gastric mucosa, but no human efficacy data exists
- Research-grade purity should be ≥98% HPLC; request batch-specific Certificates of Analysis before use
- The 10mg vial costs roughly double the 5mg format (estimated R780–R850) and reduces per-assay cost for multi-arm protocols
- Sourcing locally avoids import delays, SARS clearance and cold-chain breaks
- Institutional ethics clearance and biosafety sign-off are mandatory before any laboratory work
What Is BPC-157? A Research-Chemical Overview
BPC-157 is a synthetic pentadecapeptide of 15 amino acids (sequence GEPPPGKPADDAGLV), derived from a partial sequence identified in human gastric juice. It has been studied since the early 1990s as a cytoprotective fragment of Body Protection Compound. The peptide carries CAS number 137525-51-0, molecular formula C62H98N16O22, and molecular weight 1,419.53 g/mol. It is a research chemical, not a licensed medicine in South Africa.
Naming and identity
The peptide appears in the preclinical literature as Body Protection Compound 157, PL-10, PL 14736, or "pentadecapeptide BPC 157". Sikiric and colleagues have published the bulk of rodent tissue-repair and brain-gut axis work since 2016. South African laboratory orders should match CAS number 137525-51-0 against the supplier's batch documentation to confirm identity before reconstitution.
Regulatory status
No human medicine containing BPC-157 is registered with SAHPRA (South African Health Products Regulatory Authority). No completed human clinical trial appears on ClinicalTrials.gov or SANCTR as of May 2026. Material sold through the peptides catalogue is supplied strictly for in vitro and preclinical use, in line with the unregistered-substances framework under the Medicines and Related Substances Act.
Researchers comparing tissue-repair candidates often benchmark BPC-157 against the copper tripeptide GHK-Cu in parallel wound-healing assays.
Body Pharm BPC-157 10mg, Product Specifications
The Body Pharm BPC-157 10mg vial is a lyophilised pentadecapeptide powder for in vitro and preclinical research, containing 10mg of net peptide for reconstitution. The 10mg format roughly doubles the working stock per vial compared with the more widely listed 5mg format, which lowers per-assay cost for researchers running multi-arm tissue-repair protocols.
| Specification | Value |
|---|---|
| Manufacturer | Body Pharm |
| Form | Lyophilised powder |
| Vial size | 10mg net peptide |
| Peptide sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Purity (typical research grade) | ≥98% HPLC (request batch CoA) |
| Salt form | Not specified on vendor listing; confirm with supplier |
| Reconstitution solvent | Bacteriostatic water |
| Storage (sealed) | −20 °C, protected from light |
| Storage (reconstituted) | 2–8 °C, use within 30 days |
| Intended use | In vitro / preclinical research only |
Body Pharm's South African listings for the 5mg sibling product do not publish a batch-specific HPLC chromatogram on the product page. I request the current Certificate of Analysis from the supplier before each new experimental series and match CAS number 137525-51-0 against the documentation at goods-receipt. This confirms both identity and purity before any reconstitution begins.
Researchers building a broader tissue-repair panel can cross-reference this vial against the rest of the peptides catalogue, including the Body Pharm GHK-Cu research peptide used in parallel wound-healing assays.
BPC-157 in Tissue-Repair Research: Key Preclinical Findings
The BPC-157 evidence base is preclinical. Rodent and in vitro studies from roughly 2010 to 2023 report accelerated tendon, ligament, gastric mucosal and bone healing. The proposed mechanism centres on VEGF (Vascular Endothelial Growth Factor)-driven angiogenesis and upregulation of growth hormone receptor expression in injured tissue.
No Phase III human clinical trial of BPC-157 has been registered or completed on ClinicalTrials.gov or the South African National Clinical Trials Register as of May 2026. Every claim below applies to animal or cell-culture models only. This is standard for early-stage research peptides and does not preclude mechanistic or comparative in vitro work.
Landmark preclinical studies at a glance
| Model | Tissue | Reported outcome | Era |
|---|---|---|---|
| Rat Achilles tendon transection (Pevec et al.) | Tendon | Improved tendon-to-bone healing and biomechanical recovery at intraperitoneal microgram-per-kg doses | 2010 |
| Rat medial collateral ligament transection (Chang et al.) | Ligament | Enhanced fibroblast outgrowth and angiogenic markers; faster functional recovery | 2011 |
| Rat gastric and intestinal injury models (Sikiric et al., review) | GI mucosa | Cytoprotection and accelerated mucosal repair across ulcer, fistula and anastomosis models | 2018 |
| Musculoskeletal model review (Gwyer et al.) | Tendon, ligament, muscle, bone | Consistent pro-angiogenic and pro-healing signal across rodent studies; authors flag absence of human RCTs (Randomised Controlled Trials) | 2019 |
What the literature does and does not support
Across these studies, investigators consistently report VEGF pathway activation, nitric oxide system modulation and upregulated growth hormone receptor expression in injured fibroblasts and tenocytes as the proposed mechanism of action. Dose ranges are typically in the microgram-per-kilogram band in rodents, administered intraperitoneally, intragastrically or topically. These do not translate directly to in vitro assay concentrations and must be calibrated against your own model.
The literature does not support any human efficacy or safety conclusion. Both the 2018 and 2019 reviews note the absence of registered controlled human trials, and that position has not changed by May 2026.
For a South African laboratory procuring this vial, the defensible framing in a protocol or ethics submission is tissue-repair mechanism studies in cell culture or approved animal models. Cross-reference where useful against parallel peptides in the peptides catalogue, such as the Body Pharm GHK-Cu research peptide, which appears in adjacent wound-healing literature.
Buying BPC-157 in South Africa: What Researchers Should Know
Body Pharm BPC-157 10mg is sold in South Africa as a research chemical through specialist peptide suppliers, not pharmacies. It is not registered with SAHPRA for human or veterinary use. Local availability has stabilised since 2024, when resellers such as glp1-2u.com listed the 5mg Body Pharm vial at around R391. The 10mg vial sits at roughly double that when verified against the peptides catalogue in May 2026. Confirm the live figure at checkout, as ZAR pricing moves with import cycles.
What separates research-grade supply from grey-market listings
Three documentation points are worth requesting before ordering:
- A batch-specific HPLC chromatogram
- A Certificate of Analysis stating purity (international research-grade vendors typically advertise ≥98%)
- Confirmation of the salt form, since BPC-157 is commonly supplied as the acetate or arginine salt rather than the free acid
Body Pharm does not publish these on the public listing. Request the current CoA directly from the supplier. Batch-specific documentation is the standard verification method across South African research-peptide procurement.
10mg versus 5mg, and why local sourcing matters
For a laboratory running repeated tissue-repair assays or comparing BPC-157 against an adjacent peptide such as the Body Pharm GHK-Cu pen, the 10mg vial reduces per-milligram cost and limits reconstitution cycles.
Sourcing locally through JCSG.org, with tracked courier dispatch and discreet packaging to Johannesburg, Cape Town or Durban, avoids the import duty, SARS clearance delays and cold-chain breaks that USD-denominated international orders routinely incur.
SAHPRA Regulatory Status of BPC-157 in South Africa (2026)
BPC-157 is not a registered medicine with SAHPRA and is not listed as a scheduled substance under the Medicines and Related Substances Act 101 of 1965 when supplied strictly for in vitro or preclinical laboratory research. It has no approved human or veterinary therapeutic indication in South Africa as of May 2026. No completed human clinical trial is registered on ClinicalTrials.gov or SANCTR.
Body Pharm BPC-157 10mg is therefore sold as a research chemical only, not a medicinal product.
Any peptide marketed with therapeutic claims falls under SAHPRA's enforcement remit as an unregistered medicine. Researchers ordering through the peptides catalogue, including adjacent tissue-repair compounds such as the Body Pharm GHK-Cu pen, retain responsibility for institutional ethics clearance and biosafety sign-off under the National Health Act 61 of 2003 before any laboratory work begins.
Where to verify current scheduling
This section is not legal advice. For the live scheduling position on BPC-157 or any pentadecapeptide, query SAHPRA directly at www.sahpra.org.za and consult your institutional research ethics committee before procurement.
Reconstitution and Storage Protocol for BPC-157 10mg
Reconstitute the 10mg lyophilised vial with bacteriostatic water, 1ml for a 10mg/ml working stock, or 2ml for a 5mg/ml stock. Store the reconstituted solution at 4 °C and use within 28–30 days. The lyophilised vial remains stable at −20 °C, protected from light, until the date on the Body Pharm label.
In my own bench protocol I let the sealed vial equilibrate to room temperature for 15–20 minutes before piercing the stopper. This prevents condensation forming on the lyophilised cake, which causes uneven dissolution. I draw the bacteriostatic water into a sterile syringe and dispense it slowly down the inner glass wall rather than directly onto the peptide cake. Direct injection onto the cake creates localised shear and foaming, both of which fragment the pentadecapeptide backbone.
Once the diluent is in, I swirl gently for 30–60 seconds until the solution clears. No vortexing, no vigorous inversion, mechanical agitation denatures peptide secondary structure. If multiple experiments are planned, I aliquot the reconstituted stock into low-protein-binding microtubes, because each freeze-thaw cycle measurably reduces recoverable peptide. For comparative tissue-repair work alongside the Body Pharm GHK-Cu pen, I match aliquot volumes to a single experimental run to eliminate thaw-related variability.
How BPC-157 Compares to Related Research Peptides
BPC-157 is the only common tissue-repair research peptide derived from a sequence found in human gastric juice. That origin is why preclinical literature spans both gastrointestinal and musculoskeletal models rather than a single tissue type, and it distinguishes BPC-157 from the three peptides researchers most often place alongside it.
| Peptide | Sequence origin | Primary research focus |
|---|---|---|
| BPC-157 | Gastric pentadecapeptide fragment | GI mucosa, tendon, ligament, neurovascular repair |
| GHK-Cu | Endogenous copper-binding tripeptide | Dermal wound healing, fibroblast signalling |
| IGF-1 LR3 | Recombinant IGF-1 (Insulin-like Growth Factor 1) analogue (Arg³, N-terminal extension) | Myocyte proliferation, anabolic tissue growth |
| TB-500 | Synthetic fragment of thymosin β-4 | Actin sequestration, cell migration |
For wound-healing comparisons, the GHK-Cu research peptide is the most direct counterpart given its dermal focus. IGF-1 LR3 and TB-500 sit further from the GI-repair axis. The full peptides catalogue lists the related vials for cross-referencing. Combination protocols fall outside this page and require independent in vitro design and dose-response work.
Frequently Asked Questions, BPC-157 Research Chemical SA
Is BPC-157 legal to buy in South Africa for research?
BPC-157 is not a SAHPRA-registered medicine and may only be supplied and held for in vitro or preclinical research use under the Medicines and Related Substances Act, 1965 (Act 101 of 1965). No SAHPRA notice between 2023 and May 2026 names BPC-157 specifically. Any human or veterinary therapeutic claim falls under SAHPRA enforcement.
What purity should research-grade BPC-157 have?
Research-grade BPC-157 should be ≥98% pure by HPLC, with a batch-specific Certificate of Analysis available on request. International reference vendors routinely advertise 99%+ HPLC purity for 10mg vials. Body Pharm-specific CoA documentation for the 10mg vial is supplied on request to laboratories rather than published on the product page.
How much BPC-157 is in a Body Pharm 10mg vial?
A Body Pharm BPC-157 10mg vial contains 10 milligrams of lyophilised pentadecapeptide powder, twice the 5mg format listed by other South African resellers in 2024. The salt form (free acid, acetate, or arginine) is not stated on public listings and should be confirmed via batch documentation from the supplier before experimental use.
Does BPC-157 need to be kept cold during shipping?
Lyophilised BPC-157 is stable at ambient temperature for short transit periods. Insulated tracked courier delivery of 1–3 business days to Johannesburg, Cape Town and Durban is typically sufficient. Once reconstituted, the solution requires 2–8 °C refrigeration. Confirm current cold-chain arrangements directly with the supplier before placing an order.
What is the difference between BPC-157 and BPC-157 Arginine Salt?
BPC-157 free acid and BPC-157 arginine salt share the same 15-amino-acid sequence but differ in counter-ion. The arginine salt form shows improved aqueous solubility and reconstitution behaviour compared with the free acid. Researchers cross-referencing tissue-repair peptides can review the peptides catalogue for related vials.
Next Steps for South African Researchers
If you are planning to procure Body Pharm BPC-157 10mg for tissue-repair research, begin by contacting your institutional research ethics committee to confirm whether your proposed protocol requires formal approval. Once ethics clearance is in place, request a current Certificate of Analysis from the supplier and verify the batch CAS number (137525-51-0) against the documentation. Confirm the salt form and ZAR pricing at checkout, then arrange local courier delivery through JCSG.org to minimise cold-chain risk. Store the sealed vial at −20 °C until reconstitution, and follow the bench protocol above to preserve peptide integrity across your experimental series.
